Growth Metrics

Pfizer (PFE) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $209.0 billion.

  • Pfizer's Liabilities and Shareholders Equity fell 477.32% to $209.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $836.5 billion, marking a year-over-year decrease of 534.59%. This contributed to the annual value of $213.4 billion for FY2024, which is 599.3% down from last year.
  • According to the latest figures from Q3 2025, Pfizer's Liabilities and Shareholders Equity is $209.0 billion, which was down 477.32% from $206.1 billion recorded in Q2 2025.
  • Pfizer's 5-year Liabilities and Shareholders Equity high stood at $227.0 billion for Q4 2023, and its period low was $41.1 billion during Q4 2022.
  • For the 5-year period, Pfizer's Liabilities and Shareholders Equity averaged around $185.6 billion, with its median value being $206.1 billion (2025).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 1121.83% in 2022, then soared by 42269.49% in 2023.
  • Quarter analysis of 5 years shows Pfizer's Liabilities and Shareholders Equity stood at $181.5 billion in 2021, then grew by 8.67% to $197.2 billion in 2022, then grew by 15.11% to $227.0 billion in 2023, then dropped by 5.99% to $213.4 billion in 2024, then fell by 2.06% to $209.0 billion in 2025.
  • Its last three reported values are $209.0 billion in Q3 2025, $206.1 billion for Q2 2025, and $208.0 billion during Q1 2025.